Amazing work, exciting to see continued progress in the acute pancreatitis space. Each step forward builds momentum toward better treatments and outcomes for all pancreatitis patients.
Our new paper published today provides new hope to patients suffering from acute pancreatitis due to very severe hypertriglyceridemia (TG >880 mg/dl) also called familial chylomicronemia syndrome- plozasarin reduced the risk of recurrent pancreatitis by 83% and risk of hospitalization and duration of stay in the hospital. No traditional drug has been prospectively shown to reduce the risk of recurrent hypertriglyceridemia-induced AP, likely because traditional therapies that have been available until recently such as statins, fibrates and fish oils generally are supportive in nature and produce modest reductions in TGs. However, a new generation of therapies has emerged that potently inhibit apolipoprotein C-III (ApoC3) production in the liver and reduce long-term TGs to levels not previously deemed possible. Plozasiran is a small interfering RNA (siRNA) that silences ApoC3 leading to reduction in plasma TG and reducing the risk of recurrent acute pancreatitis. UC San Diego Nicholas Leeper Arrowhead Pharmaceuticals Colin Howden Patty Maysent Pradeep Khosla Ariel Feldstein Alexander Khalessi, MD, MBA Grace Su American Association for the Study of Liver Diseases (AASLD) John Carethers, MD, MACP, FAACR Vikesh Singh Mandeep Sawhney Pancreatic Cancer Action Network The National Pancreas Foundation Société Francaise du Pancréas Pancreas Center HSR Anne Marie Lennon MD PhD David C Whitcomb MD PhD Yehuda Handelsman Pam Rajendran Taub, MD FACC FASPC Michael Wilkinson, MD, FACC, FNLA Vinod Rustgi AIG Hospitals Anand Kulkarni David Weinberg Barbara Jung Zea Borok Bryan Clary Christine Chung, M.D. Sonia Ramamoorthy Naresh Soni Mohamed Othman Mohamed El-Kassas William D Chey Anirban Maitra Diane M. Simeone Miguel Regueiro Dr Shiv Kumar Sarin Vincent Wong